WOODCLIFF LAKE, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer Inc.'s Xanax XR (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The company intends to launch its product immediately.
Xanax XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.
Barr's Alprazolam Extended-Release tablets will compete in a market that had total annual sales of approximately $83 million for the twelve months ending May 2006, according to IMS sales data.
Source: Barr Pharmaceuticals, Inc.